BACKGROUND: The combination of paclitaxel and carboplatin has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancer patients previously treated with 5-fluorouracil and platinum. METHODS: Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel (200 mg/m(2) for 3 h) and carboplatin [area under the concentration-time curve (AUC = 6)] on day 1 and in 21 day cycles. RESULTS: A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. CONCLUSIONS: Combination chemotherapy with paclitaxel and carboplatin is feasible in patients with advanced gastric cancer who were previously treated with 5-fluorouracil and platinum.
BACKGROUND: The combination of paclitaxel and carboplatin has been used to treat patients with many types of tumor, including gastric cancer. We evaluated the efficacy and safety of this combination in advanced gastric cancerpatients previously treated with 5-fluorouracil and platinum. METHODS:Patients who had pathologically been proven to have measurable lesions were treated with paclitaxel (200 mg/m(2) for 3 h) and carboplatin [area under the concentration-time curve (AUC = 6)] on day 1 and in 21 day cycles. RESULTS: A partial response was achieved in 10 of 45 patients [22%, 95% confidence interval (CI), 10-34]. Of the 32 patients previously treated with cisplatin, four (13%) achieved partial response, whereas, of the 13 patients previously treated with heptaplatin, six (46%) achieved partial response. In all patients, the median time to progression was 14 weeks (95% CI, 10-18), and the median overall survival was 32 weeks (95% CI, 26-38). The most common grade 3/4 adverse events were neutropenia (40% of patients) and neuropathy (2.2%). Two patients developed neutropenic fever. However, there were no treatment-related deaths. CONCLUSIONS: Combination chemotherapy with paclitaxel and carboplatin is feasible in patients with advanced gastric cancer who were previously treated with 5-fluorouracil and platinum.
Authors: Oscar Arrieta; Cynthia Villarreal-Garza; Digna Pachuca; Rosa M Michel Ortega; Luis Martinez-Barrera; Diana Flores-Estrada; Alma Astorga Journal: Med Oncol Date: 2010-01-05 Impact factor: 3.064
Authors: M Joerger; C Schaer-Thuer; D Koeberle; K Matter-Walstra; J Gibbons-Marsico; S Diem; B Thuerlimann; T Cerny Journal: Eur J Clin Pharmacol Date: 2014-03-11 Impact factor: 2.953
Authors: Mohammad Mobayed; Lance K Heilbrun; Anthony F Shields; Tara Washington; Raghu Venkatramanamoorthy; Philip A Philip; Bassel F El-Rayes Journal: Case Rep Oncol Date: 2009-11-21
Authors: Sina Vatandoust; Tim Bright; Amitesh Chandra Roy; David Watson; Susan Gan; Jeff Bull; Muhammad Nazim Abbas; Christos Stelios Karapetis Journal: BMJ Open Date: 2019-05-05 Impact factor: 2.692
Authors: Keun Wook Lee; Jee Hyun Kim; Tak Yun; Eun Kee Song; Im Il Na; Hyunchoon Shin; So Yeon Oh; In Sil Choi; Do Youn Oh; Dong Wan Kim; Seock Ah Im; Tae You Kim; Jong Seok Lee; Dae Seog Heo; Yung Jue Bang; Noe Kyeong Kim Journal: J Korean Med Sci Date: 2007-09 Impact factor: 2.153